Development of myeloproliferative disease in 12/15-lipoxygenase deficiency

摘要

We read with interest the report by Kinder and colleagues at the Wistar Institute along with their related studies2-3 showing that 12/15-lipoxygenase (LOX)-deficiency in (C57BL/6, N11) mice leads to severe myeloproliferative disease (MPD). Moderate splenomegaly with 100 percent penetrance was observed at 10-12 weeks, with profound blood leukocytosis and basophilia. The defect was characterized as loss of hematopoeitic stem cell function, with reductions in lymphocytes, monocytes, and eosinophils. Furthermore, mortality was enhanced to approximately 25 percent by 12 months.3 Strikingly, up to 15percent of 10- to 12-week-old animals became moribund, and were considered in blast crisis, with grossly enlarged spleens at up to 6-fold normal size (mean 0.6 g). As the strain has existed for approximately 18 years with no apparent ill health, we decided to examine several 12/15-LOX-deficient mouse colonies in different locations.